Delving into the Latest Updates on viDA Therapeutics, Inc. with Synapse

作者: Liggins, Richard ; Wu, Zhenguo ; Raithatha, Sheetal A ; Cameron, Dale R ; Papp, Anthony ; Arns, Steve ; Jaquith, James ; Zhao, Hongyan ; Shen, Yue ; Granville, David J ; Turner, Christopher T ; Zeglinski, Matthew R ; Zeng, Haishan ; Russo, Valerio ; Bozin, Tatjana ; Tan, Jason ; Hiroyasu, Sho ; Boey, Anthony ; Nabai, Layla ; Kopko, Irina ; Huang, Rachel ; Oram, Cameron ; Westendorf, Kathryn

Granzyme B (GzmB) is a serine protease that has long been thought to function exclusively in lymphocyte-mediated apoptosis. In recent years, this paradigm has been revisited due to the recognition that GzmB accumulates in the extracellular milieu in many autoimmune and chronic inflammatory disorders, and contributes to impaired tissue remodeling due to the cleavage of extracellular matrix proteins. Knockout studies suggest that GzmB-mediated cleavage of decorin (DCN) contributes to impaired collagen fibrillogenesis and remodeling. As DCN is anti-fibrotic and contributes to reduced hypertrophic scarring, GzmB-induced DCN cleavage could play a role in wound healing following burn injury. In the present study, a novel, gel-formulated, first-in-class small-molecule inhibitor of GzmB, VTI-1002, was assessed in a murine model of impaired, diabetic burn wound healing. VTI-1002 exhibited high specificity, potency, and target selectivity. Gel-formulated VTI-1002 was able to penetrate the stratum corneum and was retained in the skin with minimal systemic absorption. Daily topical administration of VTI-1002 gel for 30 days following thermal injury showed significantly accelerated wound closure, increased DCN protein levels, and collagen organization that was translated into significantly increased wound tensile strength compared to controls. Overall, VTI-1002 gel was well-tolerated in vivo and no adverse events were observed. Topical application of VTI-1002 represents a novel therapeutic approach for the treatment of cutaneous burn wounds.

100 项与 viDA Therapeutics, Inc. 相关的药物交易

登录后查看更多信息

100 项与 viDA Therapeutics, Inc. 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2024年12月23日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

临床前

8

2

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

VDA-007 ( GZMK )	免疫系统疾病更多	临床前
VDA-001 ( GRB )	大疱性类天疱疮更多	临床前
VTI-1002 ( GRB )	自身免疫性疾病更多	临床前
VDA-006 ( GRB )	免疫系统疾病更多	临床前
VDA-002 ( GZMK )	免疫系统疾病更多	临床前